DK1565212T3 - Gastrinsammensætninger og formuleringer, og fremgangsmåde til anvendelse og fremstilling - Google Patents

Gastrinsammensætninger og formuleringer, og fremgangsmåde til anvendelse og fremstilling

Info

Publication number
DK1565212T3
DK1565212T3 DK03778179T DK03778179T DK1565212T3 DK 1565212 T3 DK1565212 T3 DK 1565212T3 DK 03778179 T DK03778179 T DK 03778179T DK 03778179 T DK03778179 T DK 03778179T DK 1565212 T3 DK1565212 T3 DK 1565212T3
Authority
DK
Denmark
Prior art keywords
seq
residues
gastrin
amino acid
formulations
Prior art date
Application number
DK03778179T
Other languages
English (en)
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1565212T3 publication Critical patent/DK1565212T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK03778179T 2002-11-21 2003-11-21 Gastrinsammensætninger og formuleringer, og fremgangsmåde til anvendelse og fremstilling DK1565212T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42810002P 2002-11-21 2002-11-21
US42856202P 2002-11-22 2002-11-22
US43059002P 2002-12-03 2002-12-03
US51993303P 2003-11-14 2003-11-14
PCT/CA2003/001778 WO2004045640A1 (en) 2002-11-21 2003-11-21 Gastrin compositions and formulations, and methods of use and preparation

Publications (1)

Publication Number Publication Date
DK1565212T3 true DK1565212T3 (da) 2008-02-25

Family

ID=32330051

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03778179T DK1565212T3 (da) 2002-11-21 2003-11-21 Gastrinsammensætninger og formuleringer, og fremgangsmåde til anvendelse og fremstilling

Country Status (14)

Country Link
US (3) US20040266682A1 (da)
EP (3) EP1837031B1 (da)
JP (2) JP2006513719A (da)
KR (1) KR20050083933A (da)
AT (1) ATE378065T1 (da)
AU (1) AU2003285229C1 (da)
BR (1) BR0316489A (da)
CA (1) CA2505167A1 (da)
DE (1) DE60317554T2 (da)
DK (1) DK1565212T3 (da)
MX (1) MXPA05005330A (da)
NO (1) NO20053027L (da)
PL (1) PL376622A1 (da)
WO (1) WO2004045640A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
ATE411077T1 (de) 2001-01-12 2008-10-15 Waratah Pharmaceuticals Inc Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
ES2334268T3 (es) 2002-06-07 2010-03-08 Waratah Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de la diabetes.
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
CN1781023A (zh) * 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
CA2554458A1 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
CA2571957A1 (en) * 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
AU2006301892A1 (en) * 2005-10-07 2007-04-19 Waratah Pharmaceuticals, Inc. Combined use of DPP IV inhibitors and gastrin compounds
KR20100059867A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 밴드 ３ 단백질 및 ｐａｃａｐ－２７의 용도
KR20100056506A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 항―ｈｉｖ제로서의 부갑상선 호르몬 （１－３４）의 용도
AU2010232989A1 (en) * 2009-04-03 2011-09-22 The University Of Toledo A PEG-albumin composition having at least one protected thiol region as a platform for medications
KR101286721B1 (ko) * 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
US9040660B2 (en) * 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
JP5969461B2 (ja) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用
CN102260868A (zh) * 2011-07-22 2011-11-30 上海交通大学 高耐蚀性钝化液及其生产工艺
TW201326194A (zh) * 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
CA2867611A1 (en) * 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c1-inhibitors
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
AU2018283284A1 (en) 2017-06-15 2020-01-30 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
EP0284898A3 (de) * 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
EP0380230B1 (en) * 1989-01-24 1994-11-17 Aphton Corporation Immunogenic compositions against gastrin peptides
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
ATE196548T1 (de) * 1991-05-10 2000-10-15 Genentech Inc Auswählen von agonisten und antagonisten von liganden
WO1993003757A1 (en) 1991-08-16 1993-03-04 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
ES2185663T3 (es) * 1994-01-24 2003-05-01 Waratah Pharmaceuticals Inc Tratamiento de la diabetes.
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
DE19514087A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
US6423685B1 (en) * 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US20040037818A1 (en) 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2351522A1 (en) 1998-11-19 2000-05-25 Samantha Busfield Egf-like nucleic acids and polypeptides and uses thereof
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
CN100475953C (zh) 1999-12-06 2009-04-08 通用医疗公司 胰腺干细胞
AU2001233502B2 (en) 2000-02-18 2006-02-02 The Walter And Eliza Hall Institute Of Medical Research Pancreatic islet cell growth factors
WO2002010195A2 (en) 2000-08-02 2002-02-07 Theratechnologies Inc. Modified peptides with increased potency
ATE411077T1 (de) * 2001-01-12 2008-10-15 Waratah Pharmaceuticals Inc Zusammensetzungen, welche gastrin/cck- rezeptorligande und egf-rezeptorligande enthalten,zur induzierung der neogenese von inselzellen
CA2442177A1 (en) 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
ES2334268T3 (es) 2002-06-07 2010-03-08 Waratah Pharmaceuticals, Inc. Procedimientos y composiciones para el tratamiento de la diabetes.
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
ES2320754T3 (es) 2002-10-22 2009-05-28 Waratah Pharmaceuticals, Inc. Tratamiento de la diabetes.
US20040229810A1 (en) 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
AU2004233911A1 (en) 2003-04-30 2004-11-11 Waratah Pharmaceuticals, Inc. Combined use of keratinocyte growth factor agonists and gastrin compounds
MXPA05012605A (es) 2003-05-27 2006-02-22 Waratah Pharmaceuticals Inc Composiciones que comprenden compuestos de gastrina y sus usos en la diabetes.
CA2554458A1 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
CA2571957A1 (en) 2004-07-01 2006-01-12 Waratah Pharmaceuticals, Inc. Methods and compositions using cd3 agonists
AU2006301892A1 (en) 2005-10-07 2007-04-19 Waratah Pharmaceuticals, Inc. Combined use of DPP IV inhibitors and gastrin compounds
EP1971363A1 (en) 2005-12-02 2008-09-24 Waratah Pharmaceuticals, Inc. Combination treatments with gastrin agonists for diabetes and related diseases
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

Also Published As

Publication number Publication date
US20110034379A1 (en) 2011-02-10
AU2003285229B2 (en) 2009-07-30
NO20053027D0 (no) 2005-06-20
WO2004045640A1 (en) 2004-06-03
EP1837031B1 (en) 2009-10-14
PL376622A1 (pl) 2006-01-09
US20090075873A1 (en) 2009-03-19
EP1884247A3 (en) 2008-02-13
MXPA05005330A (es) 2005-10-26
CA2505167A1 (en) 2004-06-03
BR0316489A (pt) 2005-10-11
EP1565212B1 (en) 2007-11-14
AU2003285229A1 (en) 2004-06-15
DE60317554T2 (de) 2008-09-18
ATE378065T1 (de) 2007-11-15
US7803766B2 (en) 2010-09-28
JP2006513719A (ja) 2006-04-27
NO20053027L (no) 2005-08-22
KR20050083933A (ko) 2005-08-26
EP1837031A1 (en) 2007-09-26
US20040266682A1 (en) 2004-12-30
JP2010265294A (ja) 2010-11-25
DE60317554D1 (de) 2007-12-27
EP1565212A1 (en) 2005-08-24
EP1884247A2 (en) 2008-02-06
AU2003285229C1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
DK1565212T3 (da) Gastrinsammensætninger og formuleringer, og fremgangsmåde til anvendelse og fremstilling
Minamino et al. Neuromedin C: a bombesin-like peptide identified in porcine spinal cord
HK1119955A1 (en) Modified kunitz domain polypeptide
AU633913B2 (en) Novel tnf-inhibit proteins and their preparation
DK165988B (da) Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c
CA2291963A1 (en) Tumor necrosis factor receptor-derived peptide analogues
DK0831938T3 (da) Radiomærkede peptidsammensætninger til stedspecifik målsögninger
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
CA2439598C (en) Modified derivatives of cck-8
AU2002238701A1 (en) Modified derivatives of CCK-8
HENSCHEN Disulfide bridges in the middle part of human fibrinogen
JPH0222292A (ja) 高カルシウム体液性因子拮抗薬
Adermann et al. Isolation, characterization and synthesis of a novel pardaxin isoform
WO2004016647A3 (en) Fragments of proinsulin c-peptide
Miura et al. Isolation and amino acid sequences of two trypsin inhibitors from the seeds of bitter gourd (Momordica charantia)
AU2865801A (en) Therapeutic peptides
AR059646A1 (es) Compuestos analogos a los secretagogos peptidicos de la hormona de crecimiento y preparaciones que los contienen
Carlquist Solid phase synthesis of a 31-residue fragment of human glucose-dependent insulinotropic polypeptide (GIP) by the continuous flow polyamide method
Seyer et al. Covalent structure of collagen: Amino acid sequence of three cyanogen bromide-derived peptides from human α1 (V) collagen chain
Ötvös et al. Coupling difficulty following replacement of Tyr with HOTic during synthesis of an analog of an EGF B‐loop fragment
MORODER et al. Studies on Immunoassays of Peptide Factors. II. Fluorescence Enzyme Immunoassay for Human Little-Gastrin
ATE425988T1 (de) Peptide mit affinitat fur ein phospholipid und deren verwendung
EP1225183A3 (en) Human G-protein coupled receptor
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
Tachibana et al. Copyright© 1981 by Kodansha Ltd., Tokyo